Phase 2 trial shows 83% of adults treated with survodutide achieve significant improvement in MASHUp to 83.0% of adults treated with survodutide (Boehringer Ingelheim and Zealand Pharma) achieved a statistically significant improvement...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment3 days ago